José Zhou, How the Interplay Between Efficacy and Safety in Clinical Trials Matters for Drug Development, Neurotherapeutics, 32, 5, (636),.

Kathleen A. F. Schulze, Michael J. F. Tiedje and Jennifer M. Heffner, Dosing the FDA Re-Appraisal : The Role of the Quality of Clinical Data and Interim Estimation, Annals of Internal Medicine, 160, 5, (521-523),.

M.A. van der Bremt and M.W.F. de Zwaan, Psychosocial considerations in drug trials, International Journal of Drug Policy, 16, 4, (317-328),.

I. S. O’Boyle, A. H. Murray‐Giddings and J.G. Stroud, The impact of trial selection, sample size and quality on treatment outcomes and cost to society, European Review of Clinical Pharmacology, 21, 3, (229-238),.

Julia M. Martin and David J. Woodman, An updated assessment of the scientific literature and scientific evidence for the effectiveness of antidepressants for depression, European Review of Clinical Pharmacology, 21, 1, (57-75),.

D. C. H. Gollobin, The importance of study quality: a review of the literature, International Review of Psychiatry, 30, 3, (217),.

J. H. Schuller, A. R. Fisch and S. J. Schuller, A reexamination of an analysis of drug drug interactions, Pharmacology Biochemistry and Behavior, 61, 1-2, (31),.

D. S. Hahn, B. R. Krumholz and V. W. Krumholz, Drugs that do not alter heart rate (HRD) and cardiovascular-related side effects and events can be effective in depression when given as monotherapy, Clinical Pharmacology & Therapeutics, 80, 1, (73),.

M. E. Fyfe and M. J. O’Donohoe, Meta‐analysis: effects of study design on the precision of meta‐analysis, BMJ Open, 3, 9, (e001224),.